HeimCRSP • NASDAQ
add
Crispr Therapeutics AG
46,70 $
Eftir lokun(1,07%)+0,50
47,20 $
Lokað: 26. jún., 19:48:34 GMT-4 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
47,66 $
Dagbil
45,60 $ - 47,55 $
Árabil
30,06 $ - 63,68 $
Markaðsvirði
4,03 ma. USD
Meðalmagn
2,39 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 865,00 þ. | 71,63% |
Rekstrarkostnaður | 19,30 m. | 7,48% |
Nettótekjur | -136,00 m. | -16,64% |
Hagnaðarhlutfall | -15,72 þ. | 32,04% |
Hagnaður á hvern hlut | -1,58 | -10,49% |
EBITDA | -143,69 m. | -5,84% |
Virkt skatthlutfall | -0,82% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,86 ma. | -11,99% |
Heildareignir | 2,17 ma. | -11,19% |
Heildarskuldir | 336,94 m. | -5,11% |
Eigið fé alls | 1,83 ma. | — |
Útistandandi hlutabréf | 86,36 m. | — |
Eiginfjárgengi | 2,25 | — |
Arðsemi eigna | -16,84% | — |
Ávöxtun eigin fjár | -17,65% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -136,00 m. | -16,64% |
Handbært fé frá rekstri | -53,95 m. | -149,15% |
Reiðufé frá fjárfestingum | -19,76 m. | 79,80% |
Reiðufé frá fjármögnun | 10,59 m. | -96,54% |
Breyting á handbæru fé | -63,07 m. | -119,84% |
Frjálst peningaflæði | -15,60 m. | -110,51% |
Um
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Framkvæmdastjóri
Stofnsett
2013
Höfuðstöðvar
Vefsvæði
Starfsfólk
393
